AbCellera Investor Conference Presentation Deck

CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 22 LARGE DIVERSIFIED PORTFOLIO IN NEXT-GEN ANTIBODY THERAPIES Portfolio of 131 programs with downstream participation is diversified across the following therapeutic areas: 39% human health, to be determined n = 51 58% oncology 50% human health, known n = 65 17% neurology 6% immunology 6% ophthalmology 5% infectious disease 3% dermatology 5% other 11% animal health n = 15

View entire presentation